Class II Peptide-Major Histocompatibility Complex Lipid Nanoparticles Enable in vivo mRNA Delivery to Antigen-Specific CD4+ T Cells.
Saved in:
| Title: | Class II Peptide-Major Histocompatibility Complex Lipid Nanoparticles Enable in vivo mRNA Delivery to Antigen-Specific CD4+ T Cells. |
|---|---|
| Authors: | Choy J; Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Cheng L; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Patel M; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Zhu Y; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Ma J; Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Kang SS; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Jain M; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Biggs BA; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Schneck JP; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Mao HQ; Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States. |
| Source: | ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2026 Feb 11; Vol. 18 (5), pp. 7818-7829. Date of Electronic Publication: 2026 Feb 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 101504991 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1944-8252 (Electronic) Linking ISSN: 19448244 NLM ISO Abbreviation: ACS Appl Mater Interfaces Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
